article thumbnail

Formularies, Formulary Strategies, and Vigilante Formulary Review

Ramblings of a pharmacist

Health insurance providers do the same, and usually outsource this function to Pharmacy Benefit Managers. The point here is to make the process of obtaining these products so difficult that the patient will a) give up and take nothing or b) discuss with their physician a switch to a covered alternative.

article thumbnail

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents

Putting Patients First Blog

Recognizing both the potential benefits and challenges of the MPPP rollout, the NHC views the introduction of these documents as crucial for educating beneficiaries on their options, easing transitions, and possibly lessening the financial impact of prescription costs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Build back better: US pharma and the future of healthcare

pharmaphorum

While recent years have seen an increase in the number of people who are insured, growth in out-of-pocket costs for many people with commercial insurance has outpaced growth in health plan costs, and premiums continue to rise. In the document, PhRMA recommends several policy changes. We all need to do better.”. About the author.

article thumbnail

NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms

Putting Patients First Blog

The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.

article thumbnail

External control arms and debunking real-world data myths

pharmaphorum

Beyond the FDA, other institutions have documented what industry standards should look like in assessing RWD in a regulatory context. This can require new processes, technologies and an organisation mind shift.”. Furthermore, ECAs are well-documented in the post-approval setting.

article thumbnail

NHC’s comments in response to the 2025 Notice of Benefit and Payment Parameters (NBPP)

Putting Patients First Blog

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

article thumbnail

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

PharmaShots

Anas Batikhi: The healthcare sector, an ongoing evolving industry on its own, is simply a flowing stream of processes, revenues & valuable health outcomes. Getting this process wrong is detrimental to any revenue collections resulting from availing services to the patient.